乳腺癌的精准医学：现实还是乌托邦？
Precision medicine in breast cancer: reality or utopia?
作者信息
Bettaieb Ali, Paul Catherine, Plenchette Stéphanie, Shan Jingxuan, Chouchane Lotfi, Ghiringhelli François
机构信息
Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000, Paris, France.
LIIC, EA7269, Université de Bourgogne Franche Comté, 21000, Dijon, France.
出版信息
J Transl Med. 2017 Jun 17;15(1):139. doi: 10.1186/s12967-017-1239-z.
Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.
包括乳腺癌在内的许多癌症，由于靶向治疗的发现，已显示出预后和支持方面的优势。这些新方法的出现标志着精准医学的兴起，精准医学有助于改善癌症的诊断、预后和治疗。精准医学考虑到患者及其肿瘤的分子和生物学特异性，这些特异性会影响医生确定的治疗方案。通过分子遗传学平台、高速测序仪的发展以及这些数据的分析手段，可以进入这个医学新时代。尽管本综述中描述了在包括乳腺癌在内的癌症治疗中取得了惊人的成果，但并非所有患者都能从这一新策略中受益。这似乎与许多基因突变有关，这些突变在不同患者之间或同一患者体内可能有所不同。这就需要从技术和生物学角度为研究提供新的动力，以使所有人都能实现精准医学的希望。
Zotero 插件